PharmSource - Bio/Pharma CapEx Trends 2016

PUNE, INDIA, January 17, 2017 /EINPresswire.com/ -- GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/839766-pharmsource-bio-pharma-capex-trends-2016

Summary
Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”
According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Scope
- Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
- It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
- It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.

Reasons to buy
- The 16-page report provides important insight that you won’t find in any other source. This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Table of Content: Key Points
Executive Summary 1
Introduction 2
CapEx Overview 3
CapEx Relative to Other Financial Indicators 6
Nature of Capital Expenditure - What Is Being Built 8
What It Means 10
Appendix 12
Recently Announced and Completed Investments by Global Bio/Pharma Companies 12
Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies 14
Selected CapEx Investments by Generic Companies 2014 Onwards 15

List of Tables
Table 1 Composition of the PharmSource Universe
Table 2 Analysis of Identified CapEx Projects
Table 3 Location of Identified CapEx Projects

List of Figures
Figure 1 CapEx by Company Sector 2015
Figure 2 Comparison of CapEx Change to Revenue Change 2010-2015
Figure 3 CapEx Trends at Bio/Pharma Companies 2010-2015
Figure 4 CapEx Spend and Growth Rate for Global Bio/Pharma Companies
Figure 5 Cash Spent on Dividends, Share Repurchase and CapEx by Selected US Global Bio/Pharma Companies 2010-2015
Figure 6 Capital Expenditure for Leading Public CDMOs

ACCESS REPORT @ https://www.wiseguyreports.com/reports/839766-pharmsource-bio-pharma-capex-trends-2016

Related Reports:
PharmSource - Market Opportunities for Contract Manufacturers in Antibody Drug Conjugates
PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2016 Edition
PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2016 Edition

Entire Bundle Purchase @ 35% Discount
Offer valid till 31 January

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here